Cadrenal Therapeutics, Inc. Common Stock
CVKD
$0.60
Change (1 day)
$32.55
Year High
$5.40
Year Low
Categories
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Earnings for Cadrenal Therapeutics, Inc. Common Stock (CVKD)
Earnings in 2023 (TTM): $-8,357,086
According to Cadrenal Therapeutics, Inc. Common Stock's latest financial reports the company's current earnings (TTM) are $-8,357,086. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Cadrenal Therapeutics, Inc. Common Stock
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-8,357,086 | $-8,357,086 |
| 2022 | $-6,714,329 | $-6,714,329 |